TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31738696

Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative (FBF)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Charisma Smart Composite (CSC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Equia Forte Fil (EF)
Number of subjects: 54
Study: 31574878

Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 3 mg every 8 hours for 4 days or until ICU discharge
Number of subjects: 154

Group type: COMPARATOR
Intervention: Normal saline (equal volume)
Number of subjects: 154
Study: 27789297

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa treatment
Number of subjects: 0
Study: 26427781

Group type: EXPERIMENTAL
Intervention: Hands-on CAD/CAM module (32 students)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Video-supported lecture (Control group, 24 students)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Post-module questionnaire (48 students from both groups)
Number of subjects: 56
Study: 23432682

Group type: EXPERIMENTAL
Intervention: High-depletion condition (manipulated through watching a video requiring visual attention or completing an incongruent Stroop task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-depletion condition (control group)
Number of subjects: 0
Study: 21787825

Group type: EXPERIMENTAL
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device at 240, 480, and 690 μg doses
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via Dolphin™ device
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intranasal Shigella flexneri 2a Invaplex 50 vaccine via pipette at 240 μg dose
Number of subjects: 36
Study: 19659978

Group type: EXPERIMENTAL
Intervention: Brief educational and skills training intervention alone
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Brief educational and skills training intervention with partner assistance
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Male patients assisted by female partners
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Older couples
Number of subjects: 130
Study: 16430625

Group type: EXPERIMENTAL
Intervention: Bi-basel periprostatic nerve block (PPNB)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Bi-apical periprostatic nerve block (PPNB)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Probe introduction
Number of subjects: 143
Study: 14718713

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of 1-octanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11434165

Group type: COMPARATOR
Intervention: Dietary antioxidants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low manganese intake
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low intake of antioxidant components (zinc, copper, manganese, vitamin E, vitamin C)
Number of subjects: 36
Study: 10068731

Group type: EXPERIMENTAL
Intervention: Regular diet (Group 1)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Clear liquids (Group 2)
Number of subjects: 132
Study: 8299318

Group type: EXPERIMENTAL
Intervention: 349U85 hydrochloride (doses from 2 mg to 250 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 349U85 hydrochloride
Number of subjects: 27
Study: 2847994

Group type: EXPERIMENTAL
Intervention: Oral delta‐9‐tetrahydrocannabinol (THC), 15 mg/m2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Prochlorperazine (PCZ), 10 mg
Number of subjects: 36
Study: 31670603

Group type: EXPERIMENTAL
Intervention: Naringenin 150 mg from an extract of whole oranges standardized to 28% naringenin, taken three times/day for 8 weeks
Number of subjects: 1
Study: 31301434

Group type: EXPERIMENTAL
Intervention: SRP and irrigation with CUR solution (100 mg/L)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRP and LED irradiation (465-485 nm, 60 s)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRP, irrigation with CUR solution (100 mg/L), and LED irradiation (465-485 nm, 60 s)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SRP (Control group)
Number of subjects: 25
Study: 28764691

Group type: EXPERIMENTAL
Intervention: High-flexion TKA
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 26615377

Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5mg/kg/IV
Number of subjects: 50

Group type: COMPARATOR
Intervention: Midazolam 0.01 mg/kg/IV and ketamine 1 mg/kg/IV
Number of subjects: 50
Study: 24045663

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 0
Study: 21353655

Group type: EXPERIMENTAL
Intervention: 75 second television commercial demonstrating behind-the-scenes techniques used to artificially enhance media models
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Music videos and ordinary television commercials
Number of subjects: 87

Group type: COMPARATOR
Intervention: Television and commercials featuring no people (control group)
Number of subjects: 87
Study: 18304147

Group type: EXPERIMENTAL
Intervention: Individual counseling/education session by an atopic dermatitis educator
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 151
Study: 17142334

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional acid-etched technique with control adhesive (Transbond)
Number of subjects: 34
Study: 12660676

Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation (VF)
Number of subjects: 15042

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia (VT)
Number of subjects: 15042

Group type: EXPERIMENTAL
Intervention: Both VF and VT
Number of subjects: 15042

Group type: COMPARATOR
Intervention: Neither VF nor VT
Number of subjects: 15042

Group type: EXPERIMENTAL
Intervention: Late arrhythmias (>48 hours after enrollment)
Number of subjects: 15042
Study: 11522187

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: vCP205 vaccine with SF-2 rgp120
Number of subjects: 49
Study: 9573498

Group type: EXPERIMENTAL
Intervention: High-dose therapy with lisinopril
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low-dose therapy with lisinopril
Number of subjects: 3164

Group type: EXPERIMENTAL
Intervention: Medication use variation
Number of subjects: 3164
Study: 7923519

Group type: EXPERIMENTAL
Intervention: One-lung ventilation (OLV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two-lung ventilation (TLV)
Number of subjects: 30
Study: 3408038

Group type: EXPERIMENTAL
Intervention: Diltiazem (loading dose 0.5 mg.kg‐1 followed by infusion of 5 micrograms.kg‐1.min‐1)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Diltiazem and Placebo
Number of subjects: 66
Study: 31630532

Group type: EXPERIMENTAL
Intervention: Comprehensive early rehabilitation for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psycho-educational consultations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-hospital exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-discharge exercise training
Number of subjects: 0
Study: 30433862

Group type: EXPERIMENTAL
Intervention: 5 mg/kg oral BH4 (BH4-5)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 20 mg/kg oral BH4 (BH4-20)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 29
Study: 28787518

Group type: EXPERIMENTAL
Intervention: Visian Implantable Collamer Lens (ICL) implantation in the ciliary sulcus
Number of subjects: 18
Study: 26438119

Group type: EXPERIMENTAL
Intervention: mDCF (fluorouracil 2,000 mg/m2 IV over 48 hours, docetaxel 40 mg/m2 IV on day 1, cisplatin 40 mg/m2 IV on day 3, every 2 weeks)
Number of subjects: 85

Group type: COMPARATOR
Intervention: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2, and fluorouracil 750 mg/m2 IV over 5 days with granulocyte colony‐stimulating factor, every 3 weeks)
Number of subjects: 85
Study: 24821270

Group type: EXPERIMENTAL
Intervention: MI + education
Number of subjects: 350

Group type: COMPARATOR
Intervention: education alone
Number of subjects: 350
Study: 23039034

Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r) 40/10 mg twice daily if 2-4 kg and 80/20 mg twice daily if >4 kg
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Lamivudine 7.5 mg twice daily if 2-4 kg, 25 mg twice daily if 4-8 kg and 50 mg twice daily if >8 kg
Number of subjects: 1500
Study: 19874149

Group type: EXPERIMENTAL
Intervention: Visual Function Index ‐ VF‐14
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Visual impairment, self‐reported poor vision, dependence in daily activities, cognitive impairment, depressive symptoms, female gender, older age
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: VA of less than 6/18 in the better eye
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: VA of less than 6/12
Number of subjects: 1160
Study: 17700042

Group type: EXPERIMENTAL
Intervention: S 17092 (100, 200, 400 or 600 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15516262

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) photocoagulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Argon green laser (514 nm)
Number of subjects: 30
Study: 11192866

Group type: EXPERIMENTAL
Intervention: Azodicarbonamide (ADA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9452280

Group type: EXPERIMENTAL
Intervention: Regimen A: Berlin-Frankfurt-Munster (BFM) 76/79
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Regimen B: LSA2-L2 with cranial irradiation
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Regimen C: LSA2-L2 without cranial irradiation
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Regimen D: New York (NY) regimen
Number of subjects: 694

Group type: COMPARATOR
Intervention: Historic group
Number of subjects: 694
Study: 8747561

Group type: EXPERIMENTAL
Intervention: Neostigmine 35 micrograms/kg during atracurium block
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neostigmine 35 micrograms/kg during vecuronium block
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Neostigmine 70 micrograms/kg during atracurium block
Number of subjects: 45
Study: 2677956

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 105

Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 105
Study: 406561

Group type: EXPERIMENTAL
Intervention: Intravenous insulin therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subcutaneous insulin therapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intramuscular insulin therapy
Number of subjects: 45
Study: 30443924

Group type: EXPERIMENTAL
Intervention: Good adherence to HTN treatment
Number of subjects: 2362

Group type: EXPERIMENTAL
Intervention: Poor adherence to HTN treatment
Number of subjects: 2362

Group type: EXPERIMENTAL
Intervention: Treatment adherence
Number of subjects: 2362
Study: 26933140

Group type: EXPERIMENTAL
Intervention: Mobile device (iPad)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobile device (iTouch)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional test platform
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficients
Number of subjects: 60
Study: 25821405

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg/kg administered 30 seconds before induction
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no remifentanil)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Remifentanil group
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 151
Study: 23445184

Group type: EXPERIMENTAL
Intervention: Caregiver-mediated medication management
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Caregiver characteristics (age, cognitive ability, depressive symptoms)
Number of subjects: 91
Study: 21388549

Group type: EXPERIMENTAL
Intervention: Enteral rosuvastatin administered once daily for 14 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Matched placebo administered once daily for 14 days
Number of subjects: 80
Study: 19270824

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with capecitabine and cisplatin
Number of subjects: 18
Study: 17355494

Group type: EXPERIMENTAL
Intervention: Thioctic acid 600 mg p.o./day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15121727

Group type: EXPERIMENTAL
Intervention: parecoxib 40 mg i.v.
Number of subjects: 36

Group type: COMPARATOR
Intervention: ketorolac 30 mg i.v.
Number of subjects: 36
Study: 11402509

Group type: EXPERIMENTAL
Intervention: Eccentric contractions only
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Eccentric contractions with a 5s stretch
Number of subjects: 37
Study: 9734679

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 375

Group type: COMPARATOR
Intervention: Parenteral gold
Number of subjects: 375
Study: 9277060

Group type: EXPERIMENTAL
Intervention: Alternative Prenatal Care Visit Schedule (APCVS) (n = 43)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Traditional Prenatal Care Visit Schedule (TPCVS) (n = 38)
Number of subjects: 81
Study: 1820894

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg)
Number of subjects: 8
Study: 6294699

Group type: EXPERIMENTAL
Intervention: C-terminal octapeptide of cholecystokinin (CCK-8, 4 ng . kg‐1 . min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study: 30654453

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HYPO) and exercise (5 days/week, 80⁻85% HRmax)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Eucaloric diet (EU) and exercise (5 days/week, 80⁻85% HRmax)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HYPO)
Number of subjects: 16
Study: 28849796

Group type: EXPERIMENTAL
Intervention: 1-step universal adhesive (All-Bond Universal: AU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: 2-step self-etch adhesive (Optibond XTR: OX)
Number of subjects: 57
Study: 26607392

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (800 μg/day for 16 weeks)
Number of subjects: 62
Study: 24882698

Group type: EXPERIMENTAL
Intervention: MI Sxscore high tertile (≥19)
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: MI Sxscore intermediate tertile (11-18)
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: MI Sxscore low tertile (≤10)
Number of subjects: 1132

Group type: COMPARATOR
Intervention: BMS (bare-metal stents)
Number of subjects: 1132

Group type: COMPARATOR
Intervention: BES (biolimus-eluting stents)
Number of subjects: 1132
Study: 22294059

Group type: EXPERIMENTAL
Intervention: Lercanidipine administered in the fasted state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lercanidipine administered 15 min before a standard breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lercanidipine taken immediately after a carbohydrate-rich meal
Number of subjects: 0
Study: 21120303

Group type: EXPERIMENTAL
Intervention: Segmental stabilization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Superficial strengthening
Number of subjects: 30
Study: 18507563

Group type: EXPERIMENTAL
Intervention: Nursing educational intervention (brief education and counselling)
Number of subjects: 3522
Study: 15934121

Group type: EXPERIMENTAL
Intervention: High-intensity exercise program
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study: 12652460

Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM (fludarabine/cyclophosphamide/mitoxantrone)
Number of subjects: 94

Group type: COMPARATOR
Intervention: FCM alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM in follicular lymphoma
Number of subjects: 94

Group type: COMPARATOR
Intervention: FCM alone in follicular lymphoma
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM in mantle cell lymphoma
Number of subjects: 94

Group type: COMPARATOR
Intervention: FCM alone in mantle cell lymphoma
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rituximab plus FCM
Number of subjects: 94
Study: 10587334

Group type: EXPERIMENTAL
Intervention: High doses of lisinopril (32.5 to 35 mg daily)
Number of subjects: 3164

Group type: COMPARATOR
Intervention: Low doses of lisinopril (2.5 to 5.0 mg daily)
Number of subjects: 3164
Study: 9193426

Group type: EXPERIMENTAL
Intervention: High ACE activity (> 12 IU/L)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Low ACE activity (<= IU/L)
Number of subjects: 102
Study: 1554040

Group type: EXPERIMENTAL
Intervention: Progesterone suppository treatment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Not applicable (placebo-controlled)
Number of subjects: 129
Study: 2861874

Group type: EXPERIMENTAL
Intervention: Intramuscular pipothiazine palmitate (PP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30592635

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Risperidone with PT and psychostimulant
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo with PT and psychostimulant
Number of subjects: 167
Study: 29077654

Group type: EXPERIMENTAL
Intervention: NFAT-regulated gene expression monitoring
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard pharmacokinetic monitoring by cyclosporine trough levels
Number of subjects: 55
Study: 27598730

Group type: EXPERIMENTAL
Intervention: Photorefractive Keratectomy (PRK)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Small Incision Lenticule Extraction (SMILE)
Number of subjects: 74
Study: 24764147

Group type: EXPERIMENTAL
Intervention: Metformin + Pantoprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metformin + Rabeprazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 24
Study: 22985140

Group type: EXPERIMENTAL
Intervention: Home-based multicomponent physical activity counseling (PAC) intervention
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 302
Study: 19413520

Group type: EXPERIMENTAL
Intervention: MRI screening in women with inherited mutations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrasonography in asymptomatic women with dense breasts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer-aided detection (CAD)
Number of subjects: 0
Study: 17307440

Group type: EXPERIMENTAL
Intervention: Papillary muscle repositioning (PMR group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Complete preservation of all chordal structures with mitral valve replacement (CMVR group)
Number of subjects: 100
Study: 15144393

Group type: EXPERIMENTAL
Intervention: UVA 5 J/cm(2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UVA 10 J/cm(2)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: UVA 20 J/cm(2)
Number of subjects: 78
Study: 11278152

Group type: EXPERIMENTAL
Intervention: Medicated schizophrenic patients during initial assessment after receiving medication
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Medicated schizophrenic patients after sustained treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: First-episode schizophrenic patients (medication-naïve or not)
Number of subjects: 56
Study: 8301625

Group type: EXPERIMENTAL
Intervention: Belladonna 30C
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 3595576

Group type: EXPERIMENTAL
Intervention: 0.75% halothane
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.5% enflurane
Number of subjects: 22
Study: 30149417

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once a day for 12 weeks
Number of subjects: 24
Study: 30037778

Group type: EXPERIMENTAL
Intervention: Donepezil 5-10 mg daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 26540028

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/d) for 12 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Erlotinib-induced skin rash
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: LOH-positive patients
Number of subjects: 150
Study: 25682903

Group type: EXPERIMENTAL
Intervention: Low-intensity lifestyle intervention program
Number of subjects: 213
Study: 23774582

Group type: EXPERIMENTAL
Intervention: 2 d · wk(‐1) of aerobic training and 2 d · wk(‐1) resistance training (2 + 2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 1 d · wk(‐1) of aerobic training and 1 d · wk(‐1) of resistance training (1 + 1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3 d · wk(‐1) of aerobic training and 3 d · wk(‐1) of resistance training (3 + 3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups (1 + 1, 2 + 2, 3 + 3)
Number of subjects: 72
Study: 21051191

Group type: EXPERIMENTAL
Intervention: modified Constraint‐Induced Movement Therapy followed by Bimanual Training (mCIMT‐BiT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 52
Study: 18484473

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam plus amikacin (PTA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Carbapenem monotherapy (imipenem or meropenem)
Number of subjects: 87
Study: 17139586

Group type: EXPERIMENTAL
Intervention: Short-acting insulin analogs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analyses of short-acting insulin analogs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cochrane Review 2005
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recommendations from IQWiG
Number of subjects: 0
Study: 12538750

Group type: EXPERIMENTAL
Intervention: New comorbidity indices developed in the modeling set
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Existing comorbidity indices (Khan, Davies, Charlson)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Individual comorbidities
Number of subjects: 1041
Study: 11783322

Group type: EXPERIMENTAL
Intervention: Longshoudan (LSD) treatment for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routinely treated ACI patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 40
Study: 9355424

Group type: EXPERIMENTAL
Intervention: Endotracheal suctioning
Number of subjects: 0
Study: 1489125

Group type: EXPERIMENTAL
Intervention: MK-571
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12